P-Cure CEO: "Completion of the financing round will enable us to make the smart medical solution we have developed accessible to any oncological center that offers radiotherapy.
The Israeli company has developed the CAPTIS device for reducing the risk of stroke and other complications during catheter-based structural heart procedures.
The volume and extent of the closure was not disclosed, but is probably similar to IBF's first fund, which raised $70 million.
Sonovia is applying technology from Bar-Ilan University to make hospitals safer, and the fashion industry greener.
Nextar CEO Orna Dreazen told the Women's Health Innovations and Inventions Congress in Tel Aviv that more needs to be known about the impact of cannabis on women.
US investment bank Morgan Stanley has downgraded Teva to "Underperform", citing renewed pressure on generics prices.
Inmode had sales of $100 million last year of its aesthetic and medical treatment devices, and is profitable.
The primary efficacy endpoint of the study was the ability of C-Scan to correctly identify patients with polyps and the patients without polyps.
IBI Investment House pharma analyst Steven Tepper thinks that the legal risks threatening Teva are being overpriced.
The US president has ordered his staff to prepare an order lowering prescription drug prices in the US.
The trial for Sol-Gel's Epsolay for treating rosacea achieved all its endpoints.
The company's market cap is more than double what it was when it was delisted.
Some investors have filed a lawsuit following Ori Yehudai's abrupt resignation as chairman of the cannabis company.
Yehudai, who built Frutarom into a company sold for $7.1 billion, is stepping down as executive chairman of Sadé Group.
Israeli company Savicell's product doesn't look for cancer cells, but for tell-tale immune system reactions.
Canadian Securities Exchange CEO Richard Carleton: Israel is a strong cannabis brand.
InnovaHealth cofounder Dr. Ariella Golomb talks about the sale of OrthoSpace and says the fund seeks late stage investments in orthopedic and women's health companies.
The National Institute for Biotechnology takes an innovative approach to commercializing Ben Gurion University of the Negev's groundbreaking research.
Entou Labs has developed a product that it says improves absorption of cannabis, cutting dosage, side effects, and cost.
Kare Schultz received millions of dollars of blocked shares, which he will receive if the share price reaches a certain level by November 2020.
By implanting engineered tissue from stem cells taken from the gums, the Technion's Prof. Shulamit Levenberg provides new hope for people with spinal column injuries.
Prof. Irad Ben-Gal talks to "Globes" about dual digital and physical existence, and other ways technology will challenge our present assumptions about human life.
At 55, Dr. Anda Baharav left her work as a pediatrician to found a startup that provides personalized treatment for sleep disorders.
Having 3D printed a heart, Tel Aviv University's Prof. Tal Dvir says in principle, he can regenerate any organ in the body.
Transport, energy and healthcare are three areas where big decisions loom, and determination will be needed to carry them out.
"Globes" examines what the pioneering medical cannabis reform, due to come into effect after the election, will mean for patients, doctors, and all concerned.
The times they are a-changing us